You just read:

Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes

News provided by

ReportBuyer

Sep 26, 2016, 20:57 ET